Table 4 The distribution of LRR by targeted and endocrine therapy in Her2-positive and hormone receptor-positive patients
Characteristic | Total No. | LRR | CW | SCN | Axilla | IMN |
|---|---|---|---|---|---|---|
| Â | Â | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) |
Her2 positive | 1400 | 109 (7.8) | 49 (45.0) | 63 (57.8) | 21 (19.3) | 14 (12.8) |
  Targeted therapy | 321 | 16 (5.0) | 4 (25.0) | 9 (56.3) | 2 (12.5) | 4 (25.0) |
  No targeted therapy | 1067 | 92 (8.6) | 44 (47.8) | 53 (57.6) | 19 (20.7) | 10 (10.9) |
Hormone receptor positive | 5212 | 281 (5.4) | 139 (49.5) | 134 (47.7) | 57 (20.3) | 25 (8.9) |
  Endocrine therapy | 4400 | 210 (4.8) | 95 (45.2) | 101 (48.1) | 40 (19.0) | 23 (11.0) |
  No endocrine therapy | 569 | 30 (5.3) | 21 (70.0) | 13 (43.3) | 9 (30.0) | 2 (6.7) |